SCHEMBL6003847

SCHEMBL6003847

O=C(Nc1ccc(F)c(Cl)c1)c1cc[nH]n1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
SMN1; SMN2 Q16637 5/20 0.56
NPSR1 Q6W5P4 2/20 0.56
SLC2A1 P11166 1/20 0.54
KMT2A Q03164 6/20 0.53
MAPT P10636 3/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 5/20 0.52
LMNA P02545 1/20 0.52
FADS1 O60427 1/20 0.52
TSHR P16473 1/20 0.51
MAOB P27338 1/20 0.51
ALDH1A1 P00352 1/20 0.50
HTT P42858 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23246002 0.89 MAOB (0.51) NPC1RAB9ASMN1; SMN2NPSR1SLC2A1
SCHEMBL23246094 0.88 RAB9A (0.55) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL23246073 0.87 GRM4 (0.57) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL23246023 0.82 NPC1 (0.53) NPC1RAB9ASMN1; SMN2KMT2AKDM4E
SCHEMBL168618 0.80 MEN1 (0.63) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL23246072 0.80 GRM4 (0.52) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL23246051 0.79 SMN1; SMN2 (0.46) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL23246098 0.79 CFTR (0.49) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL23245982 0.77 MEN1 (0.46) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL23246009 0.75 KCNQ3 (0.52) NPC1RAB9ASMN1; SMN2KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528792-B2 Sulfonamide compounds and the use thereof in the treatment of cancer TroBio Therapeutics Pty Ltd (AU) 2026-01-20 US disclosed
US-20240317717-A1 SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER TroBio Therapeutics Pty Ltd (AU) 2024-09-26 US disclosed
EP-4028395-A1 SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER Trobio Therapeutics Pty Ltd (AU) 2022-07-20 EP disclosed
WO-2021072487-A1 SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER TroBio Therapeutics Pty Ltd (AU) 2021-04-22 WO disclosed
US-20060183780-A1 Pyrazole compounds useful in the treatment of inflammation BIOLIPOX AB (SE) 2006-08-17 US disclosed
EP-1603897-A1 PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION Biolipox AB (SE) 2005-12-14 EP disclosed
WO-2004080999-A1 PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317717-A1 SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER STS, TP53, SQOR NPC1 4336/4885RAB9A 3639/4885SMN1; SMN2 1187/4885
US-20060183780-A1 Pyrazole compounds useful in the treatment of inflammation ALOX15, ALOX12, ALOX15B NPC1 3112/4885RAB9A 3284/4885SMN1; SMN2 4299/4885
US-12528792-B2 Sulfonamide compounds and the use thereof in the treatment of cancer SLC10A6, SLCO4C1, SLCO2A1 NPC1 1416/4885RAB9A 3784/4885SMN1; SMN2 1232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.